A Random Walk Rule for Phase I Clinical Trials
From MaRDI portal
Publication:4349992
Recommendations
Cited in
(29)- Randomized group up and down experiments
- A new look at evaluating MTD designs in cancer research
- A new design of the continual reassessment method
- scientific article; zbMATH DE number 524373 (Why is no real title available?)
- Dose finding using the biased coin up-and-down design and isotonic regression
- Group up-and-down designs for dose-finding
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Individualized dosing for multiple ordered groups of patients
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- An application of reinforced urn processes to determining maximum tolerated dose
- Adaptive clinical trial designs for phase I cancer studies
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Designs for Single- or Multiple-Agent Phase I Trials
- On optimal designs for clinical trials: an updated review
- Up-and-down experiments of first and second order
- Derivation of Exact Distributions Following an Up-and-Down Design
- Information in a two-stage adaptive optimal design
- A conversation with Nancy Flournoy
- Sequential design for binary dose-response experiments
- A drug-induced random walk
- Continual reassessment method with multiple toxicity constraints
- Operating characteristics of the standard phase I clinical trial design.
- Directed walk designs for dose-response problems with competing failure modes
- Bayesian optimal designs for phase I clinical trials
- Biometric practicesimple benchmark for complex dose finding studies
- On the consistency of the continual reassessment method with multiple toxicity constraints
- Properties of frequency distributions induced by general up-and-down methods for estimating quantiles
- A sequential design for maximizing the probability of a favourable response
This page was built for publication: A Random Walk Rule for Phase I Clinical Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4349992)
